Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 1450 • ACR Convergence 2024
Radiographic Structural Spine Assessment in Ankylosing Spondylitis According to the Presence or Absence of Psoriasis
Inès Favre-Felix¹, Andrea MENNINI², Caroline Morizot³, Marie LAFFAIRE², Isabelle Chary-Valckenaere⁴ and Damien Loeuille⁵, ¹Nancy university, Vandœuvre-lès-Nancy, France, ²CHRU Nancy, Nancy, France, ³CHRU Nancy, Vandœuvre-lès-Nancy, France, ⁴Nancy University Hospital, Vandœuvre-lès-Nancy, Lorraine, France, ⁵Phd, Nancy Vandoeuvre, Lorraine, France
Background/Purpose: Patients with ankylosing spondylitis and psoriasis (AS-Pso) were classically older, smokers, overweighted, with lower prevalence of the HLA-B27 status and an equal sex ratio…
Abstract Number: 1985 • ACR Convergence 2024
Underlying Autoimmune Disease Has Not Limited Immune Checkpoint Inhibitor Use or Increased Mortality Risk During Cancer Treatment of US Veterans
Madeline O’Sullivan¹, grant Cannon², Sauer brian³, Jorge Rojas⁴, Gary Kunkel⁵, Jessica A Walsh⁶, Punyasha Roul⁷, shardool Patel¹, Joshua Baker⁸, Bryant England⁹ and Tawnie Braaten¹, ¹University of Utah, Salt Lake City, UT, ²University of Utah and Salt Lake City VA, Salt Lake City, UT, ³Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁴Seattle VA, Mexico, Mexico, ⁵University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁶Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁷UNMC, Omaha, NE, ⁸University of Pennsylvania, Philadelphia, PA, ⁹University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Immune checkpoint inhibitors (ICIs) can cause a variety of immune-related adverse events (irAEs) affecting multiple organ systems, and patients with pre-existing autoimmune disease (AID)…
Abstract Number: 0078 • ACR Convergence 2024
Inhibition of the Deubiquitinase TRABID in a Pre-clinical Mouse Model of Axial Spondyloarthritis Decreases Disease Severity
Archita Srinath¹, Daniele Mauro², Mariia Korshko³, Shaghayegh Foroozan⁴, Mansi Aparnathi⁵, Francesco Ciccia⁶ and Nigil Haroon⁷, ¹University of Toronto, Toronto, ON, Canada, ²University of Campania, Italy, Naples, Naples, Italy, ³University Health Network, Toronto, ON, Canada, ⁴University Health Network/University of Toronto, Toronto, ON, Canada, ⁵University Health Network, Toronto, Canada, ⁶University of Campania, Naples, Italy, ⁷Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Axial Spondyloarthritis is characterized by both inflammation and new bone formation. Current therapeutic targets aim to control inflammation, however, over 40% of patients do…
Abstract Number: 0562 • ACR Convergence 2024
Serum Interleukin IL-40 as a Potential Biomarker Associated with Pro-inflammatory Activity in Inflammatory Bowel Diseases and Spondyloarthritis: A Preliminary Study
Lucia Ondrejčáková¹, Adéla Navrátilová², Monika Gregová³, Kristýna Bubová⁴, Tomáš Grega⁵, Ladislav Šenolt⁶, Karel Pavelka⁷ and Lucie Andrés Cerezo⁸, ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, ²1st Faculty of Medicine, Charles University and Institute of Rheumatology in Prague, Hlavní mesto Praha, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine Charles University, Prague, Czech Republic, ⁴Institute of Rheumatology and Charles University, Prague, Czech Republic, ⁵3Department of Internal Medicine, First Faculty of Medicine, Charles University, Military University Hospital, Prague, Czech Republic, Prague, Czech Republic, ⁶Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁷Institute of Rheumatology and Charles University, Praha, Czech Republic, ⁸Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Interleukin 40 (IL-40) is a novel cytokine with a proposed role in the pathogenesis of inflammatory diseases. Inflammatory bowel diseases (IBD)-associated with spondyloarthritis (SpA)…
Abstract Number: 1020 • ACR Convergence 2024
Health Inequalities Exist Between the United States and Europe for Patients with Axial Spondyloarthritis
Elena Nikiphorou¹, Alexis Ogdie², Dan Twigg³, Emily Quiñones⁴, You-Li Ling⁵, Karim Masri⁶, Joseph C. Cappelleri⁷, Lidia Sanchez-Riera⁸, Megan Hughes⁹ and NICOLA MASSEY⁹, ¹King's College London, London, United Kingdom, ²Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³Adelphi Real World, Manchester, United Kingdom, ⁴Adelphi Real World, Macclesfield, United Kingdom, ⁵Pfizer Inc, New York, NY, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer, Groton, ⁸Pfizer, Madrid, ⁹Adelphi Real World, Bollington, United Kingdom
Background/Purpose: Structural differences exist between the healthcare systems in the United States (US) and Europe. In real-world clinical settings, we investigated whether these differences create…
Abstract Number: 1453 • ACR Convergence 2024
Efficacy and Safety of the Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection (XKH004) in Patients with Active Ankylosing Spondylitis: Findings from a 24-Week, Phase 2 Multicenter, Randomized, Placebo-Controlled Study
Ling Zhou¹, Juan Zhao¹, Lingyun Sun², Xuan Zhang³, Xiaomei Li⁴, Jiankang Hu⁵, Lijun Wu⁶, Zhenyu Jiang⁷, Min Yang⁸, Xiaoxia Wang⁹, Yongjun Mei¹⁰, Qingchun Huang¹¹, Yongtao Chen¹², Yang Li¹³, Lingli Dong¹⁴, Hui Luo¹⁵, Li Guo¹⁶, Jianguo You¹⁶, Yunpeng Zhang¹⁶, Ke Ren¹⁶ and Huji Xu¹, ¹Shanghai Changzheng Hospital, Shanghai, China (People's Republic), ²Nanjing Drum Tower Hospital, Nanjing, China (People's Republic), ³Beijing Hospital, Beijing, China, ⁴The First Affiliated Hospital of University of Science and Technology of China, Anhui, China (People's Republic), ⁵Department of Rheumatology, Pingxiang People's Hospital, Pingxiang, China, Pingxiang, China (People's Republic), ⁶People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China (People's Republic), ⁷The First Hospital of Jilin University, Changchun, China (People's Republic), ⁸Nanfang Hospital, Guangzhou, China (People's Republic), ⁹Second Hospital of Shanxi Medical University, Taiyuan, China (People's Republic), ¹⁰The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, ¹¹The Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China (People's Republic), ¹²West China Hospital, Sichuan University, Chengdu, China (People's Republic), ¹³Guangdong Provincial People's Hospital, Guangzhou, China (People's Republic), ¹⁴Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (People's Republic), ¹⁵Xiangya Hospital, Central South University, Changsha, China (People's Republic), ¹⁶Kanova Biopharma, Zhejiang, China (People's Republic)
Background/Purpose: XKH004, the first recombinant anti-human IL-17A/F humanized monoclonal antibody in China (also known as XKH004), shares the same therapeutic target as Bimekizumab from UCB…
Abstract Number: 2049 • ACR Convergence 2024
Genetically Proxied Glucose‑lowering Drug Target and Risk of Immune Mediated Inflammatory Disease: A Mendelian Randomization Study
Dongze Wu¹ and Yingzhao jin², ¹Department of Rheumatology and Immunology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China (People's Republic), ²Department of Medicine and Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: There are conflicting findings on the relationship between glucose-lowering drugs and risk of development of immune mediated inflammatory diseases (IMIDs). The study aimed to…
Abstract Number: 0080 • ACR Convergence 2024
Enhanced Cytotoxicity of Aging Associated NKG2C+ CD8+ T Cells in Ankylosing Spondylitis via HLA-B27
Kunhai Tang, Xiaobei Ma, Jian Gao, Feng Qian, Qi Zhu, Jiucun Wang and Jing Liu, Fudan University, Shanghai, China (People's Republic)
Background/Purpose: Ankylosing spondylitis (AS) is an immune-related chronic inflammatory disease characterized by inflammatory pain in the lower back and spinal ankylosing, accompanied by immune system disorders, such…
Abstract Number: 0564 • ACR Convergence 2024
The Risk of Venous Thromboembolism in Axial Spondyloarthritis: A Population-based Study
Mayas Arraf¹, Devy Zisman², walid Saliba³, Nili Stein⁴ and Joy Feld⁵, ¹Technion medical school, Haifa, Israel, ²Carmel Medical Center, Haifa, Israel, ³Carmel medical center, Haifa, Israel, ⁴Department of Community Medicine and Epidemiology, Haifa, Israel, ⁵Carmel and Zvulun Medical Centre, Haifa, Israel
Background/Purpose: Scarce data exist regarding the incidence of venous thromboembolism events (VTE); pulmonary embolism (PE) and deep vein thrombosis (DVT), in patients with axial spondylarthritis…
Abstract Number: 1030 • ACR Convergence 2024
Diversity in Axial Spondyloarthritis Drug Trials: Examining Enrollment by Sex, Race, Ethnicity and Geographic Region
Mathieu Choufani¹, Wissam Ghusn² and Joerg Ermann³, ¹Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, ²Department of Internal Medicine, Boston Medical Center, Boston, MA, ³Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: While axial spondyloarthritis (AxSpA) was historically perceived as a "white man's disease", it is now appreciated as a condition that can affect individuals of…
Abstract Number: 1459 • ACR Convergence 2024
Dietary Modification and Intermittent Fasting Are Common in Patients with Axial Spondylarthritis and May Lead to Reduced Inflammatory Activity
Michael Nissen¹, Adrian Ciurea², Raphael Micheroli³, Eric Trunk⁴ and Delphine Courvoisier⁵, ¹Geneva University Hospital, Geneva, Switzerland, ²University Hospital Zurich, Zürich, Switzerland, ³University Hospital Zurich, Zurich, Switzerland, ⁴Geneva University Hospital, Geenva, Switzerland, ⁵University Hospitals of Geneva, Geneva, Switzerland
Background/Purpose: Current EULAR recommendations highlight the importance of a healthy, balanced diet in patients with inflammatory rheumatic disease, including axial spondylarthritis (axSpA). A Mediterranean-style diet…
Abstract Number: 2119 • ACR Convergence 2024
IL-17 Blockade Therapy Improves Symptoms in Patients with Active Axial Spondyloarthritis Without Occurrence of New Vertebral Fractures
Chloe Heiting¹, Donald McMahon¹, Douglas Mintz¹, Weijia Yuan¹, Insa Mannstadt¹, Linda A Russell¹, Emily Stein¹, Dalit Ashany² and Susan Goodman³, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Scarsdale, NY, ³Hospital for Special Surgery, New York 10025, NY
Background/Purpose: Axial spondyloarthritis (AxSpA) is characterized by abnormal bone formation and, paradoxically, bone loss accompanied by increased bone fragility and vertebral fracture risk. Tumor necrosis…
Abstract Number: 0081 • ACR Convergence 2024
The Axial Spondyloarthritis Risk Variant CARD9 S12N Enhances Neutrophil-mediated Th Responses
Hillary Struthers¹, Kofi Asare-Konadu², Emily Vance¹ and Ruth Napier³, ¹Oregon Health & Science University, Portland, OR, ²Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, OR, ³Department of Molecular Microbiology and Immunology and Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, VA Portland Health Care System, Portland, OR
Background/Purpose: Axial spondyloarthritis (axSpA) is a type of inflammatory arthritis that primarily affects the entheses of the spine and/or sacroiliac joints. The cause of axSpA…
Abstract Number: 0565 • ACR Convergence 2024
Low Vitamin D Serum Level Is a Risk Factor for Ankylosis in Axial Spondyloarthritis: Evidence from a Nested-Case-Control Study
Anthony Lichaa¹, Pauline KRUG¹ and Adrien Nzeusseu Toukap², ¹Cliniques universitaires St-Luc, Brussel, Belgium, ²Cliniques universitaires Saint-Luc,, St.-Lambrechts-Woluwe, Belgium
Background/Purpose: Axial spondyloarthritis (axSpA) is a progressive disease, characterized by chronic inflammation and progressive structural damage. However, the kinetic of progression to ankylosis and much…
Abstract Number: 1054 • ACR Convergence 2024
Utilization of Rehabilitation Services in Patients with Common Rheumatic Conditions: A Systematic Review
Keri Geinosky¹, Joel Thompson², Joshua Torrey³ and Louise Thoma⁴, ¹University of North Carolina at Chapel Hill, Chapel Hill, ²university of north carolina - chapel hill, Cary, NC, ³UNC Chapel Hill, Westmoreland, NH, ⁴University of North Carolina, Chapel Hill, NC
Background/Purpose: Rehabilitation services, such as physical therapy (PT) and occupational therapy (OT), are recommended in the care of inflammatory arthritis and other rheumatic conditions. However, the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.